Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

96 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C.
Almhanna K, Wright D, Mercade TM, Van Laethem JL, Gracian AC, Guillen-Ponce C, Faris J, Lopez CM, Hubner RA, Bendell J, Bols A, Feliu J, Starling N, Enzinger P, Mahalingham D, Messersmith W, Yang H, Fasanmade A, Danaee H, Kalebic T. Almhanna K, et al. Among authors: fasanmade a. Invest New Drugs. 2017 Oct;35(5):634-641. doi: 10.1007/s10637-017-0473-9. Epub 2017 May 19. Invest New Drugs. 2017. PMID: 28527133 Clinical Trial.
TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study.
Bang YJ, Takano T, Lin CC, Fasanmade A, Yang H, Danaee H, Asato T, Kalebic T, Wang H, Doi T. Bang YJ, et al. Among authors: fasanmade a. Cancer Res Treat. 2018 Apr;50(2):398-404. doi: 10.4143/crt.2017.074. Epub 2017 May 10. Cancer Res Treat. 2018. PMID: 28494535 Free PMC article. Clinical Trial.
Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies.
Almhanna K, Kalebic T, Cruz C, Faris JE, Ryan DP, Jung J, Wyant T, Fasanmade AA, Messersmith W, Rodon J. Almhanna K, et al. Among authors: fasanmade aa. Clin Cancer Res. 2016 Oct 15;22(20):5049-5057. doi: 10.1158/1078-0432.CCR-15-2474. Epub 2016 May 13. Clin Cancer Res. 2016. PMID: 27178743 Clinical Trial.
Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C.
Almhanna K, Miron ML, Wright D, Gracian AC, Hubner RA, Van Laethem JL, López CM, Alsina M, Muñoz FL, Bendell J, Firdaus I, Messersmith W, Ye Z, Fasanmade AA, Danaee H, Kalebic T. Almhanna K, et al. Among authors: fasanmade aa. Invest New Drugs. 2017 Apr;35(2):235-241. doi: 10.1007/s10637-017-0439-y. Epub 2017 Feb 11. Invest New Drugs. 2017. PMID: 28188407 Clinical Trial.
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck.
Brockstein B, Haraf DJ, Stenson K, Fasanmade A, Stupp R, Glisson B, Lippman SM, Ratain MJ, Sulzen L, Klepsch A, Weichselbaum RR, Vokes EE. Brockstein B, et al. Among authors: fasanmade a. J Clin Oncol. 1998 Feb;16(2):735-44. doi: 10.1200/JCO.1998.16.2.735. J Clin Oncol. 1998. PMID: 9469365 Clinical Trial.
Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials.
Lichtenstein GR, Diamond RH, Wagner CL, Fasanmade AA, Olson AD, Marano CW, Johanns J, Lang Y, Sandborn WJ. Lichtenstein GR, et al. Among authors: fasanmade aa. Aliment Pharmacol Ther. 2009 Aug;30(3):210-26. doi: 10.1111/j.1365-2036.2009.04027.x. Epub 2009 Apr 21. Aliment Pharmacol Ther. 2009. PMID: 19392858 Free article. Clinical Trial.
96 results